Charles River Laboratories International and Purespring Therapeutics, a gene therapy company dedicated to transforming the treatment of kidney diseases, have announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration. The program is aimed at supporting the first gene therapy platform targeting renal diseases, which affect around 10% of the global population, or approximately 840 million people. The collaboration will leverage Charles River's established plasmid platform, eXpDNA™, and decades of experience at the Company's plasmid DNA manufacturing center of excellence. Purespring is focused on developing novel therapies that have the potential to halt or significantly slow down chronic kidney diseases, for which there is currently no therapy available, except for dialysis or transplantation. Purespring's Adeno-Associated Virus (AAV)-based gene therapy, which targets the podocyte, a specialized kidney cell type implicated in many kidney diseases, offers a low-dose, local delivery approach that maximizes safety and efficacy, while also reducing the cost of goods.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!